Miniatura

Fitxers

Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of_ClinicalMedicine.pdf (688.69 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-06-22

Llicència de publicació

cc by (c) Alcaraz Asensio, Antonio et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/209152

Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/jcm11133615

Resum

The objective of this subset analysis was to evaluate and compare the efficacy and tolerability of two combination treatments for men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). Data were from a real-world, open-label, prospective, and multicenter study performed in outpatient urology clinics. Men with moderate-to-severe LUTS/BPH received 6-month treatment with tamsulosin (TAM) in combination with either the hexanic extract of S. repens (HESr) or a 5-alpha-reductase inhibitor (5ARI). Changes in urinary symptoms and quality of life were measured using the IPSS and BII questionnaires, respectively. Treatment tolerability was assessed by recording adverse effects (AEs). Patients in the two study groups were matched using iterative and propensity score matching approaches. After iterative matching, data were available from 136 patients (n = 68 treated with TAM + 5ARI, n = 68 with TAM + HESr). After 6 months of treatment, mean (SD) IPSS total score improved by 7.7 (6.3) and 6.7 (5.0) points in the TAM + 5ARI and TAM + HESr groups, respectively (p = 0.272); mean BII total scores improved by 3.1 (2.9) and 2.9 (2.4) points (p = 0.751), respectively. AEs were reported by 26.5% and 10.3% of patients in the same groups, mostly affecting sexual function (p < 0.027). When used in a real-world setting to treat patients with moderate-severe LUTS/BPH, 6-month treatment with TAM + HESr was as effective as TAM + 5ARI, but with better tolerability. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Matèries

Malalties de l'aparell genitourinari, Homes

Matèries (anglès)

Genitourinary organs diseases, Men

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ALCARAZ ASENSIO, Antonio, CASTRO DIAZ, David, GACCI, Mauro, SALONIA, Andrea, FICARRA, Vincenzo, CARBALLIDO RODRÍGUEZ, Joaquín, RODRÍGUEZ ANTOLÍN, Alfredo, MEDINA POLO, José, FERNÁNDEZ GÓMEZ, Jesús m., CÓZAR OLMO, José m., BÚCAR TERRADES, Santiago, PÉREZ LEÓN, Noemí, BRENES BERMÚDEZ, Francisco j., MOLERO GARCÍA, José m., FERNÁNDEZ PRO LEDESMA, Antonio, HERDMAN, Michael, ANGULO, Javier c., MANASANCH, José, QUALIPROST Study Group. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study. _Journal Of Clinical Medicine_. 2022. Vol. 11, núm. 13. [consulta: 20 de gener de 2026]. ISSN: 2077-0383. [Disponible a: https://hdl.handle.net/2445/209152]

Exportar metadades

JSON - METS

Compartir registre